Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER vs HEMICLOR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium is the major intracellular cation. It is essential for the maintenance of intracellular tonicity, nerve impulse transmission, cardiac muscle contractility, and skeletal muscle contraction. Dextrose provides a source of calories and may help to correct hypoglycemia.
Hemichlor (HEMICLOR) is a brand name for a combination product containing chlorpheniramine and pseudoephedrine. Chlorpheniramine is a first-generation antihistamine that antagonizes histamine at H1 receptor sites, reducing allergic symptoms. Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.
Replacement of potassium in patients with hypokalemia,Prevention of hypokalemia in patients who would be at risk from developing this condition,Source of calories and fluid in parenteral nutrition when potassium supplementation is required
Relief of symptoms associated with seasonal and perennial allergic rhinitis, including nasal congestion, sneezing, rhinorrhea, and pruritus,Off-label: Adjunctive treatment for acute sinusitis and common cold symptoms
Intravenous infusion at a rate not exceeding 10 m Eq/hour (0.75 m Eq/kg/hour). Typical dose: 20-40 m Eq potassium chloride in 1 liter D5W administered over 8-12 hours.
50-100 mg intravenously every 6 hours or 100 mg orally every 12 hours.
Potassium has no true elimination half-life as it is an endogenous electrolyte; redistribution half-life is approximately 1–1.5 hours for exogenous loads, reflecting cellular uptake and renal excretion. In anephric patients, half-life extends to 12–24 hours due to reliance on gastrointestinal and dialysis excretion.
Terminal elimination half-life 18–24 hours in normal renal function; prolonged to 36–48 hours in moderate renal impairment (Cr Cl 30–50 m L/min); adjust dosing interval in renal disease.
Potassium is primarily excreted unchanged by the kidneys. Dextrose is metabolized via glycolysis and subsequent pathways to carbon dioxide and water, yielding energy.
Chlorpheniramine is extensively metabolized in the liver via CYP450 enzymes, primarily CYP2D6, and excreted renally as metabolites. Pseudoephedrine is partially metabolized in the liver by N-demethylation and excreted largely unchanged in urine; its metabolism is not significantly enzyme-dependent.
Renal: >90% of potassium excreted by kidneys, with distal tubular secretion and reabsorption. Fecal: ~10% eliminated via gastrointestinal tract. Biliary: negligible.
Primarily renal (85–90% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal < 5%.
~10% bound to plasma proteins (albumin). Unbound fraction is physiologically active.
70–80% (primarily to albumin).
Total body potassium Vd ~0.5 L/kg (approximates lean body mass). For intravenously administered potassium: initial Vd approximates extracellular fluid (0.2 L/kg) with redistribution into cells over 15–30 minutes. Clinical meaning: Low Vd indicates rapid equilibration; loading doses must account for intracellular shift to avoid hyperkalemia.
0.3–0.5 L/kg (indicates moderate tissue distribution).
Intravenous: 100%. Oral: ~90% (absorbed in small intestine). No other routes relevant.
Oral: 40–60% (due to first-pass metabolism; food may reduce absorption).
GFR >50 m L/min: No adjustment. GFR 30-50 m L/min: Reduce dose by 25-50%. GFR 10-30 m L/min: Reduce dose by 50-75%. GFR <10 m L/min: Avoid use or use with extreme caution; consider alternative.
GFR 30-50 m L/min: 50 mg IV every 12h or 50 mg PO every 24h; GFR 10-29 m L/min: 50 mg IV every 24h or 25 mg PO every 24h; GFR <10 m L/min: 25 mg IV every 48h or avoid use.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 25-50% due to risk of hyperkalemia. Child-Pugh C: Avoid use; alternative therapy recommended.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Neonates and infants: 0.5-1 m Eq/kg/dose IV, not to exceed 0.5 m Eq/kg/hour. Children: 1-3 m Eq/kg/day IV, maximum infusion rate 0.5-1 m Eq/kg/hour; maximum concentration 40 m Eq/L.
5-10 mg/kg IV every 6h, max 100 mg/dose.
Start at lower end of dosing range (e.g., 10-20 m Eq per liter) and titrate slowly. Monitor renal function and serum potassium frequently. Maximum infusion rate: 5-10 m Eq/hour.
Start at lower end of dosing range (50 mg IV every 12h or 50 mg PO every 24h) due to reduced renal function and increased sensitivity.
Potassium chloride injections are for intravenous use only. Rapid infusion may cause hyperkalemia and cardiac arrest. Concentrated potassium chloride solutions (>=2 m Eq/m L) must be diluted before use. Do not administer undiluted.
No FDA black box warning is present for HEMICLOR.
Monitor serum potassium levels frequently to avoid hyperkalemia,Use with caution in patients with renal impairment, cardiac disease, or conditions predisposing to hyperkalemia,Do not administer if solution is discolored or contains particulate matter,Check for compatibility with other medications in the same line
Cardiovascular effects: Use with caution in patients with hypertension, ischemic heart disease, or arrhythmias,CNS depression: Chlorpheniramine may cause sedation; avoid concurrent use with alcohol or other CNS depressants,Monoamine oxidase inhibitor (MAOI) interaction: Concomitant use with MAOIs or within 14 days of discontinuation can precipitate hypertensive crisis,Urinary retention: Use cautiously in patients with prostatic hypertrophy or bladder neck obstruction,Photosensitivity: Chlorpheniramine may increase risk of photosensitivity reactions
Hyperkalemia,Severe renal impairment with oliguria or anuria,Conditions that cause potassium retention (e.g., Addison's disease, systemic acidosis),Hypersensitivity to potassium chloride or dextrose
Hypersensitivity to chlorpheniramine, pseudoephedrine, or any component,Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of MAOI therapy,Severe hypertension or severe coronary artery disease,Narrow-angle glaucoma,Urinary retention,Breastfeeding (relative contraindication due to pseudoephedrine excretion)
Avoid excessive consumption of potassium-rich foods (e.g., bananas, oranges, potatoes, spinach, avocados) and salt substitutes containing potassium chloride. Limit high-sodium foods as they may affect fluid and electrolyte balance.
Avoid alcohol and grapefruit juice. Take with food to reduce gastrointestinal upset. Limit caffeine intake as it may worsen anxiety or gastrointestinal symptoms.
Potassium chloride and dextrose are not teratogenic. There is no evidence of fetal harm from potassium chloride or dextrose at standard doses. Trimester-specific risks are not applicable.
Hemichlor (hydrochlorothiazide) is contraindicated in pregnancy due to risk of fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances. First trimester: associated with neural tube defects in animal studies and possible oligohydramnios. Second/third trimester: risk of fetal bradycardia, hyponatremia, hypokalemia, and decreased placental perfusion.
Potassium chloride and dextrose are endogenous substances normally present in breast milk. No safety concerns at standard doses. M/P ratio not established; not clinically relevant as both are normal milk constituents.
Hydrochlorothiazide is excreted in breast milk in low concentrations. M/P ratio approximately 0.04-0.06. No adverse effects reported in infants, but may suppress lactation at high doses. Use with caution, monitor infant for electrolyte disturbances.
No specific dose adjustment required for pregnancy; however, monitor for fluid overload and electrolyte imbalances due to increased plasma volume and GFR in pregnancy; adjust rate based on serum potassium and glucose.
Pregnancy increases volume of distribution and renal clearance of hydrochlorothiazide, potentially reducing peak serum concentration. However, due to fetal risks, thiazide diuretics are generally avoided in pregnancy. If essential, use lowest effective dose and monitor maternal/fetal status closely. No specific dose adjustment studies exist.
Administer via central line if concentration exceeds 0.1% (20 m Eq/L) to avoid phlebitis. Do not exceed infusion rate of 10 m Eq/hour. Contraindicated in severe renal impairment (Cr Cl <30 m L/min), hyperkalemia, or Addison's disease. Monitor ECG for peaked T waves and serum potassium levels. Use with caution in patients on ACE inhibitors, ARBs, or potassium-sparing diuretics.
HEMICLOR contains clidinium bromide (quaternary ammonium anticholinergic) and chlordiazepoxide (benzodiazepine). Monitor for anticholinergic side effects (dry mouth, blurred vision, urinary retention, constipation). Avoid use in patients with narrow-angle glaucoma, obstructive uropathy, or myasthenia gravis. Chlordiazepoxide may cause dependence; limit duration to 4-8 weeks. Use with caution in elderly due to increased sensitivity to anticholinergic effects and risk of falls.
Report any signs of hyperkalemia such as muscle weakness, palpitations, or tingling sensations.,Avoid potassium-containing salt substitutes or supplements unless approved by your doctor.,This solution contains dextrose; if you have diabetes, monitor blood glucose closely.,Inform your healthcare provider about all medications, especially heart or blood pressure medicines.,Do not stop or change the infusion rate on your own.
Take exactly as prescribed; do not increase dose or stop abruptly.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Avoid alcohol and other CNS depressants.,Report any signs of urinary retention, severe constipation, or blurred vision.,Do not share with others; risk of dependence.,Store at room temperature away from moisture and heat.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER vs HEMICLOR, answered by our medical review team.
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER is a Electrolyte Supplement that works by Potassium is the major intracellular cation. It is essential for the maintenance of intracellular tonicity, nerve impulse transmission, cardiac muscle contractility, and skeletal muscle contraction. Dextrose provides a source of calories and may help to correct hypoglycemia.. HEMICLOR is a Electrolyte Supplement that works by Hemichlor (HEMICLOR) is a brand name for a combination product containing chlorpheniramine and pseudoephedrine. Chlorpheniramine is a first-generation antihistamine that antagonizes histamine at H1 receptor sites, reducing allergic symptoms. Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER and HEMICLOR depend on the specific clinical indication. These are both Electrolyte Supplement agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion at a rate not exceeding 10 m Eq/hour (0.75 m Eq/kg/hour). Typical dose: 20-40 m Eq potassium chloride in 1 liter D5W administered over 8-12 hours.. The standard adult dose of HEMICLOR is: 50-100 mg intravenously every 6 hours or 100 mg orally every 12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER and HEMICLOR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Potassium chloride and dextrose are not teratogenic. There is no evidence of fetal harm from potassium chloride or dextrose at standard doses. Trimester-specific risks are not appl. HEMICLOR is classified as Category C. Hemichlor (hydrochlorothiazide) is contraindicated in pregnancy due to risk of fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances. First trimester: associated . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.